Glucagon-like peptide 1 receptor agonists appear to reduce the risk of age-related macular degeneration and primary open-angle glaucoma.

If you’ve been paying attention to the weight loss world, you’ve probably heard about GLP-1 receptor agonists like Ozempic, ...

Researchers found that GLP-1 receptor agonists (GLP-1RAs) significantly reduce the risk of several blood cancers in type 2 ...

Discover how peptides are transforming medical treatments, metabolic conditions and more with fewer side effects than ...

GLP-1 receptor agonists are not associated with an increased risk for suicidality compared with DPP-4 inhibitors or SGLT-2 inhibitors.

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced presentation of preclinical data supporting the advancement of ...

A naturally occurring molecule identified by Stanford Medicine researchers appears similar to semaglutide—also known as ...

Novo Nordisk (NVO) plans to study how its GLP-1 drugs marketed as Wegovy and Ozempic for obesity and diabetes can help tackle ...

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) Q4 2024 Earnings Call Transcript March 4, 2025 Amylyx Pharmaceuticals, Inc.

GLP-1 receptor agonists show promise in treating alcohol addiction by modulating reward pathways and reducing cravings, offering a novel therapeutic approach.

Drug developers' dreams of silencing RNA as a way to step in front of a range of diseases have not lived up to early-day hype ...

Background Effective management of coexisting heart failure (HF), chronic kidney disease (CKD) and type 2 diabetes mellitus ...